Sander van Deventer

8.0k total citations · 3 hit papers
62 papers, 4.9k citations indexed

About

Sander van Deventer is a scholar working on Genetics, Immunology and Molecular Biology. According to data from OpenAlex, Sander van Deventer has authored 62 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Genetics, 20 papers in Immunology and 17 papers in Molecular Biology. Recurrent topics in Sander van Deventer's work include Inflammatory Bowel Disease (20 papers), Microscopic Colitis (10 papers) and Virus-based gene therapy research (5 papers). Sander van Deventer is often cited by papers focused on Inflammatory Bowel Disease (20 papers), Microscopic Colitis (10 papers) and Virus-based gene therapy research (5 papers). Sander van Deventer collaborates with scholars based in Netherlands, United States and Canada. Sander van Deventer's co-authors include Stefan Schreiber, Paul Rutgeerts, Geert D’Haens, Maikel P. Peppelenbosch, Daan W. Hommes, Filip Baert, T Schaible, Douglas M. Chalmers, Karel Geboes and Brian G. Feagan and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Experimental Medicine.

In The Last Decade

Sander van Deventer

62 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations

2001 837 citations Jochen Hampe, Andrew Cuthbert et al. The Lancet profile →
Natalizumab Induction and Maintenance Therapy for Crohn's Disease

2005 688 citations William J. Sandborn, Jean‐Frédéric Colombel et al. New England Journal of Medicine profile →
Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1999 585 citations Geert D’Haens, Sander van Deventer et al. Gastroenterology profile →

Peers

Countries citing papers authored by Sander van Deventer

Since Specialization

Citations

This map shows the geographic impact of Sander van Deventer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sander van Deventer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sander van Deventer more than expected).

Fields of papers citing papers by Sander van Deventer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sander van Deventer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sander van Deventer. The network helps show where Sander van Deventer may publish in the future.

Co-authorship network of co-authors of Sander van Deventer

This figure shows the co-authorship network connecting the top 25 collaborators of Sander van Deventer. A scholar is included among the top collaborators of Sander van Deventer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sander van Deventer. Sander van Deventer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting oxidized phosphatidylcholines in SOD1-associated ALS: therapeutic potential of PC-OxPL-VecTab® 2025 ·Frontiers in Neuroscience ·(unknown), (unknown), Rob Haselberg, (unknown), Sander van Deventer	1
2	Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease models 2024 ·Brain ·(unknown), Christian Landles, Nicholas S. Caron, (unknown), Georgina F Osborne, Michael R. Hayden, David Howland, Sander van Deventer, Gillian P. Bates, Astrid Vallès, Melvin M. Evers	9
3	25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future 2021 ·Gut ·Geert D’Haens, Sander van Deventer	92
4	Transfer of Therapeutic miRNAs Within Extracellular Vesicles Secreted from Huntington’s Disease iPSC-derived Neurons (4548) 2020 ·Neurology ·(unknown), Jana Miniarikova, (unknown), Sander van Deventer, Pavlina Konstantinova, Melvin M. Evers	4
5	Acquiring orphans 2014 ·Nature Biotechnology ·(unknown), (unknown), Sander van Deventer	5
6	Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver 2013 ·Gene Therapy ·(unknown), Joanne Verheij, Chris van der Loos, (unknown), Gerrit K. Hooijer, Raygene Martier, Florie Borel, Jacek Lubelski, Annemart Koornneef, Bas Blits, Sander van Deventer, Harald Petry, Pavlina Konstantinova	10
7	Embedding siRNA sequences targeting Apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy 2012 ·Molecular Therapy ·(unknown), Jacek Lubelski, (unknown), Florie Borel, Bas Blits, (unknown), Adalberto Costessi, Derek Butler, Sander van Deventer, Harald Petry, Annemart Koornneef, Pavlina Konstantinova	22
8	Apolipoprotein B Knockdown by AAV-delivered shRNA Lowers Plasma Cholesterol in Mice 2011 ·Molecular Therapy ·Annemart Koornneef, (unknown), (unknown), Florie Borel, Bas Blits, Tita Ritsema, Sander van Deventer, Harald Petry, Pavlina Konstantinova	27
9	Molecular Therapy for Obesity and Diabetes Based on a Long-Term Increase in Hepatic Fatty-Acid Oxidation §Δ 2010 ·Hepatology ·Josep Maria Orellana‐Gavaldà, Laura Herrero, (unknown), Astrid Pañeda, Maria Sol Rodríguez-Peña, Harald Petry, Guillermina Asins, Sander van Deventer, Fausto G. Hegardt, Dolors Serra	114
10	Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency 2010 ·Atherosclerosis Supplements ·Daniel Gaudet, J. de Wal, Karine Tremblay, S. Déry, Sander van Deventer, Andreas P. Freidig, Diane Brisson, Julie Méthot	86
11	In Vitro and In Vivo Down-Regulation of Regulatory T Cell Activity with a Peptide Inhibitor of TGF-β1 2008 ·The Journal of Immunology ·Lucía Gil‐Guerrero, Javier Dotor, Inge L. Huibregtse, Noëlia Casares, (unknown), Francesc Rudilla, José Ignacio Riezu‐Boj, Jacinto López‐Sagaseta, José Hermida, Sander van Deventer, Jaione Bezunartea, Diana Llópiz, Pablo Sarobe, Jesús Prìeto, Francisco Borrás‐Cuesta, Juan José Lasarte	57
12	Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis 2007 ·Endoscopy ·Evelien Dekker, F. van den Broek, Johannes B. Reitsma, James C.H. Hardwick, G. J. A. Offerhaus, Sander van Deventer, Daan W. Hommes, Paul Fockens	220
13	Specific Inhibition of c-Raf Activity by Semapimod Induces Clinical Remission in Severe Crohn’s Disease 2005 ·The Journal of Immunology ·Mark Löwenberg, Auke P. Verhaar, Bernt van den Blink, Fibo Ten Kate, Sander van Deventer, Maikel P. Peppelenbosch, Daniël W. Hommes	41
14	Natalizumab Induction and Maintenance Therapy for Crohn's Disease breakdown → 2005 ·New England Journal of Medicine ·William J. Sandborn, Jean‐Frédéric Colombel, (unknown), Brian G. Feagan, Stephen B. Hanauer, Ian C. Lawrance, Remo Panaccione, Martin E. Sanders, Stefan Schreiber, Stephan R. Targan, Sander van Deventer, Ronald Goldblum, Darrin Despain, Gary S. Hogge, Paul Rutgeerts	688
15	Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function 2004 ·American Journal of Clinical Nutrition ·Henri Braat, Jan Van den Brande, (unknown), Daan W. Hommes, Maikel P. Peppelenbosch, Sander van Deventer	180
16	IL-18-Binding Protein Expression by Endothelial Cells and Macrophages Is Up-Regulated During Active Crohn’s Disease 2002 ·The Journal of Immunology ·Anne Corbaz, Tessa ten Hove, Suzanne Herren, Pierre Graber, Boris Schwartsburd, Ilana Belzer, Jillian Harrison, Thomas Plitz, Marie Kosco‐Vilbois, Soohyun Kim, Charles A. Dinarello, Daniela Novick, Sander van Deventer, Yolande Chvatchko	72
17	Inflammatory signal transduction in Crohn’s disease and novel therapeutic approaches 2002 ·Biochemical Pharmacology ·Catherine van Montfrans, Maikel P. Peppelenbosch, Anje A. te Velde, Sander van Deventer	16
18	Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease 2002 ·Gastroenterology ·Daan W. Hommes, Bernt van den Blink, Terry F. Plasse, J. F. W. M. Bartelsman, Cuiping Xu, (unknown), Guido N.J. Tytgat, Maikel P. Peppelenbosch, Sander van Deventer	307
19	Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations breakdown → 2001 ·The Lancet ·Jochen Hampe, Andrew Cuthbert, Peter J.P. Croucher, Muddassar M. Mirza, Silvia Mascheretti, Sheila Fisher, H Frenzel, Kathy King, (unknown), (unknown), Stephen Bridger, Sander van Deventer, Alastair Forbes, Susanna Nikolaus, John Edward Lennard-Jones, Ulrich R. Foelsch, Michael Krawczak, Cathryn M. Lewis, Stefan Schreiber, Christopher G. Mathew	837
20	Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial breakdown → 1999 ·Gastroenterology ·Geert D’Haens, Sander van Deventer, (unknown), Douglas M. Chalmers, (unknown), Filip Baert, (unknown), T Schaible, Karel Geboes, Paul Rutgeerts	585

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact